N. Sarver

发表

The potential use of catalytic RNAs in therapy of HIV infection and other diseases.

J. Rossi, E. Cantin, N. Sarver, 1991, Pharmacology & therapeutics.

Ribozymes as potential anti-HIV-1 therapeutic agents.

J. Rossi, E. Cantin, N. Sarver, 1990, Science.

Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648.

J. Greenberger, J. Sobolewski, G. Chiang, 1999, Human gene therapy.

Utilization of an Epstein-Barr virus replicon as a eukaryotic expression vector.

J. Foulke, N. Sarver, C. Cheadle, 1988, Gene.

EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain.

A. Ullrich, I. Lax, J. Schlessinger, 1991, The Journal of biological chemistry.

Bovine Papillomavirus DNA Vectors

P. Howley, N. Sarver, 1986 .

Enhancer-dependent expression of the rat preproinsulin gene in bovine papillomavirus type 1 vectors

P. Howley, R. Muschel, G. Khoury, 1985, Molecular and cellular biology.

Transformation and replication in mouse cells of a bovine papillomavirus--pML2 plasmid vector that can be rescued in bacteria.

P. Howley, N. Sarver, J. Byrne, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Bovine papilloma virus deoxyribonucleic acid: a novel eucaryotic cloning vector

P. Gruss, P. Howley, G. Khoury, 1981, Molecular and cellular biology.

Cellular distribution of HIV type 1 Nef protein: identification of domains in Nef required for association with membrane and detergent-insoluble cellular matrix.

R. Margalit, N. Sarver, H. Drummer, 1994, AIDS research and human retroviruses.

Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications.

N. Sarver, J. Cohen, I. Green, 1989, Journal of the National Cancer Institute.

Bovine Papillomavirus Shuttle Vectors

P. Howley, W. Mcallister, N. Sarver, 1983 .

Expression oftheRatPreproinsulin Genein BovinePapillomavirus Type1 Vectors

P. Howley, R. Muschel, G. Khoury, 1985 .

Eukaryotic cloning vectors derived from bovine papillomavirus DNA.

P. Howley, N. Sarver, M. Law, 1983, Methods in enzymology.

RAT INSULIN GENE COVALENTLY LINKED TO BOVINE PAPILLOMAVIRUS DNA IS EXPRESSED IN TRANSFORMED MOUSE CELLS

P. Gruss, P. Howley, G. Khoury, 1981 .

Molecular characterization of HIV1 Nef protein.

N. Sarver, A. Panet, M. Gorecki, 1992, Research in virology.

Expression and biochemical characterization of human immunodeficiency virus type 1 nef gene product

N. Sarver, A. Panet, Z. Yavin, 1990, Journal of virology.

Nucleic acid vaccines

N. Sarver, F. Vogel, 1995, Clinical microbiology reviews.

HIV proteinase as a target for drug action.

N. Sarver, M. Johnston, H. Allaudeen, 1989, Trends in pharmacological sciences.

Gene therapy for HIV-1 infection.

D. Kohn, N. Sarver, 1996, Advances in experimental medicine and biology.

Sindbis virus-induced cytopathic effect in clones of Aedes albopictus (Singh) cells.

V. Stollar, N. Sarver, 1977, Virology.

Localization and analysis of bovine papillomavirus type 1 transforming functions

P. Howley, Y. Yang, N. Sarver, 1984, Journal of virology.

Chapter 18 – OBSERVATIONS RELATED TO CYTOPATHIC EFFECT IN AEDES ALBOPICTUS CELLS INFECTED WITH SINDBIS VIRUS

V. Stollar, N. Sarver, K. Harrap, 1979 .

Virazole prevents production of Sindbis virus and virus-induced cytopathic effect in Aedes albopictus cells.

V. Stollar, N. Sarver, 1978, Virology.

Antisense catalytic RNAs as therapeutic agents.

J. Rossi, N. Sarver, D. Castanotto, 1994, Advances in pharmacology.

Ribozymes: a new frontier in anti-HIV strategy.

N. Sarver, 1991, Antisense research and development.

Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.

J. Rossi, N. Sarver, 1992, Advances in experimental medicine and biology.

Antiviral Evaluation of HIV-1 Specific Ribozyme Expressed in CD4+ HeLa Cells

J. Rossi, E. Cantin, N. Sarver, 1991 .

Stable expression of recombinant factor VIII molecules using a bovine papillomavirus vector.

N. Sarver, G. Ricca, W. Drohan, 1987, DNA.

Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells

N. Sarver, A. Panet, M. Gorecki, 1991, Journal of virology.

HIV accessory proteins as therapeutic targets

N. Sarver, Roger H. Miller, 1997, Nature Medicine.

HIV Accessory Proteins: Emerging Therapeutic Targets

N. Sarver, Roger H. Miller, 1995, Molecular medicine.

Human Immunodeficiency Virus and AIDS: Insights from Animal Lentiviruses

N. Sarver, J. Cairns, S. Bridges, 2000, Journal of Virology.

Gene therapy and immune restoration for HIV disease

N. Sarver, S. Bridges, 1995, The Lancet.

Optimizing gene expression in BPV-transformed cells: effects of cell type on enhancer/promoter interaction.

R. Hodges, N. Sarver, W. Drohan, 1987, Nucleic acids research.

RNA enzymes (ribozymes) as antiviral therapeutic agents.

J. Rossi, N. Sarver, 1990, Trends in biotechnology.

Expression of acidic fibroblast growth factor cDNA confers growth advantage and tumorigenesis to Swiss 3T3 cells.

M. Jaye, J. Schlessinger, N. Sarver, 1988, The EMBO journal.

Conference summary: novel HIV therapies--from discovery to clinical proof of concept.

N. Sarver, R. Black, S. Bridges, 1996, AIDS research and human retroviruses.

Gene therapy: a bold direction for HIV-1 treatment.

J. Rossi, N. Sarver, 1993, AIDS Research and Human Retroviruses.

Mini-Review: New Viral Vectors for HIV Vaccine Delivery

N. Sarver, J. Cairns, 1998 .

Ribozymes as Therapies for AIDS a

J. Rossi, E. Cantin, N. Sarver, 1990, Annals of the New York Academy of Sciences.